SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 30, Issue 34, 2012, Pages 4262-4266

Role of comparative effectiveness research in cancer funding decisions in Ontario, Canada

(3) Hoch, Jeffrey S a Hodgson, David C b Earle, Craig C c

a ST MICHAEL'S HOSPITAL (Canada)

b PRINCESS MARGARET HOSPITAL (Canada)

c ONTARIO INSTITUTE FOR CANCER RESEARCH (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; GROWTH FACTOR; PACLITAXEL; TRASTUZUMAB;

ADVISORY COMMITTEE; BREAST CANCER; CANADA; COMPARATIVE EFFECTIVENESS; DECISION MAKING; DRUG RESEARCH; EVIDENCE BASED PRACTICE; FUNDING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; OBSERVATIONAL METHOD; PRIORITY JOURNAL; REVIEW; UNITED STATES;

CANADA; COMPARATIVE EFFECTIVENESS RESEARCH; FINANCING, GOVERNMENT; HEALTH POLICY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; ONTARIO;

EID: 84870674687 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2012.42.1958 Document Type: Review

Times cited : (6)

References (16)

1
- 84870667753
- A small cancer tumour, a giant time bomb
- May 12
- Wente M: A small cancer tumour, a giant time bomb. The Globe and Mail, May 12, 2011:F9
- (2011) The Globe and Mail
- Wente, M.¹

2
- 84870712048
- Denying herceptin was a necessary evil
- March 16
- Picard A: Denying herceptin was a necessary evil. The Globe and Mail, March 16, 2011:A5
- (2011) The Globe and Mail
- Picard, A.¹

3
- 79952904848
- Cancer drug access in Canada: Looking beyond coverage decisions
- Chafe R, Dobrow M, Coyte P, et al: Cancer drug access in Canada: Looking beyond coverage decisions. Healthc Policy 6:27-36, 2011
- (2011) Healthc Policy , vol.6 , pp. 27-36
- Chafe, R.¹ Dobrow, M.² Coyte, P.³

4
- 0028896975
- The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation
- Browman G, Levine M, Mohide E, et al: The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation. J Clin Oncol 13:502-512, 1995
- (1995) J Clin Oncol , vol.13 , pp. 502-512
- Browman, G.¹ Levine, M.² Mohide, E.³

5
- 84870699379
- The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada
- in press
- Yong J, Beca J, Hoch J: The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada. Pharmacoeconomics (in press)
- Pharmacoeconomics
- Yong, J.¹ Beca, J.² Hoch, J.³

6
- 84870720539
- Pan-Canadian Oncology Drug Review. http://www.pcodr.ca
- Pan-Canadian Oncology Drug Review

7
- 33749332084
- Coverage options for promising technologies: Medicare's 'Coverage with evidence development'
- DOI 10.1377/hlthaff.25.5.1218
- Tunis S, Pearson S: Coverage options for promising technologies: Medicare's "coverage with evidence development." Health Aff (Millwood) 25:1218-1230, 2006 (Pubitemid 44497620)
- (2006) Health Affairs , vol.25 , Issue.5 , pp. 1218-1230
- Tunis, S.R.¹ Pearson, S.D.²

8
- 73949105585
- Evidence-based approach to the introduction of positron emission tomography in Ontario, Canada
- Evans WK, Laupacis A, Gulenchyn KY, et al: Evidence-based approach to the introduction of positron emission tomography in Ontario, Canada. J Clin Oncol 27:5607-5613, 2009
- (2009) J Clin Oncol , vol.27 , pp. 5607-5613
- Evans, W.K.¹ Laupacis, A.² Gulenchyn, K.Y.³

9
- 0037036664
- Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer
- Whelan T, MacKenzie R, Julian J, et al: Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 94:1143-1150, 2002 (Pubitemid 34919051)
- (2002) Journal of the National Cancer Institute , vol.94 , Issue.15 , pp. 1143-1150
- Whelan, T.¹ MacKenzie, R.² Julian, J.³ Levine, M.⁴ Shelley, W.⁵ Grimard, L.⁶ Lada, B.⁷ Lukka, H.⁸ Perera, F.⁹ Fyles, A.¹⁰ Laukkanen, E.¹¹ Gulavita, S.¹² Benk, V.¹³ Szechtman, B.¹⁴

10
- 84870667553
- Cancer Care Ontario: New Drug Funding Program. https://www.cancercare.on. ca/cms/one.aspx?portalId=1377&pageId=11801
- New Drug Funding Program

11
- 84870700361
- Cancer Care Ontario: Evidence Building Program Policy. https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=118886
- Evidence Building Program Policy

12
- 84870718806
- Khor S: Real-world cost-effectiveness analysis of cancer drugs: Comparative effectiveness research using retrospective Canadian registry data before and after drug approval. http://healtheconomics.utoronto.ca
- Real-world Cost-effectiveness Analysis of Cancer Drugs: Comparative Effectiveness Research Using Retrospective Canadian Registry Data before and after Drug Approval
- Khor, S.¹

13
- 68249103874
- Comparative effectiveness research: A report from the Institute of Medicine
- Sox H, Greenfield S: Comparative effectiveness research: A report from the Institute of Medicine. Ann Intern Med 151:203-205, 2009
- (2009) Ann Intern Med , vol.151 , pp. 203-205
- Sox, H.¹ Greenfield, S.²

14
- 77957958434
- Legislating against use of cost-effectiveness information
- Neumann P, Weinstein M: Legislating against use of cost-effectiveness information. N Engl J Med 363:1495-1497, 2010
- (2010) N Engl J Med , vol.363 , pp. 1495-1497
- Neumann, P.¹ Weinstein, M.²

15
- 80053260953
- Iron K, Manuel D: Quality assessment of administrative data (QuAAD): An opportunity for enhancing Ontario's health data. http://www.ices.on.ca/file/ quaad-jul-07.pdf
- Quality Assessment of Administrative Data (QuAAD): An Opportunity for Enhancing Ontario's Health Data
- Iron, K.¹ Manuel, D.²

16
- 78650100635
- Symptom burden and performance status in a population-based cohort of ambulatory cancer patients
- Barbera L, Seow H, Howel D, et al: Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer 116:5767-5776, 2010
- (2010) Cancer , vol.116 , pp. 5767-5776
- Barbera, L.¹ Seow, H.² Howel, D.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.